Editor's Note
The Food and Drug Administration’s (FDA’s) Office of Biostatistics and Epidemiology is currently developing master protocols to be used in monitoring the safety and effectiveness of a COVID-19 vaccine once it is authorized or approved, in addition to postmarket surveillance requirements, the October 22 Regulatory Focus reports.
The FDA will draw on big data resources and the Centers for Disease Control and Prevention to follow the vaccines’ track records.
The protocols will be posted for public comment.
Read More >>Enhanced Recovery After Surgery (ERAS) represents a transformative approach in…
During Perioperative Nurses Week this November 10-16, we encourage you…
Takeaways Providers are generally seeking to reduce use of travelers…